British drugmaker’s new chief executive Luke Miels announces one of its biggest deals
Business live – latest updates
GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.
The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer.
Continue reading…
Source link : https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels
Author : Julia Kollewe
Publish date : 2026-06-09 07:28:00
Copyright for syndicated content belongs to the linked Source.
